96 related articles for article (PubMed ID: 7252834)
1. Cholinergic adaptations to chronic oxotremorine infusion.
Marks MJ; Artman LD; Patinkin DM; Collins AC
J Pharmacol Exp Ther; 1981 Aug; 218(2):337-43. PubMed ID: 7252834
[TBL] [Abstract][Full Text] [Related]
2. Chronic scopolamine treatment and brain cholinergic function.
Marks MJ; O'Connor MF; Artman LD; Burch JB; Collins AC
Pharmacol Biochem Behav; 1984 May; 20(5):771-7. PubMed ID: 6739517
[TBL] [Abstract][Full Text] [Related]
3. Nicotine-induced tolerance and receptor changes in four mouse strains.
Marks MJ; Romm E; Gaffney DK; Collins AC
J Pharmacol Exp Ther; 1986 Jun; 237(3):809-19. PubMed ID: 3712280
[TBL] [Abstract][Full Text] [Related]
4. Genetic influences on tolerance development with chronic oxotremorine infusion.
Marks MJ; Romm E; Collins AC
Pharmacol Biochem Behav; 1987 Aug; 27(4):723-32. PubMed ID: 3659096
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of tolerance development after chronic oxotremorine treatment.
Marks MJ; Artman LD; Collins AC
Pharmacol Biochem Behav; 1983 Jul; 19(1):103-13. PubMed ID: 6622504
[TBL] [Abstract][Full Text] [Related]
6. In vivo regulation of muscarinic cholinergic receptors in embryonic chick brain.
Meyer MR; Gainer MW; Nathanson NM
Mol Pharmacol; 1982 Mar; 21(2):280-6. PubMed ID: 7099136
[TBL] [Abstract][Full Text] [Related]
7. Ciliary muscle muscarinic binding sites, choline acetyltransferase, and acetylcholinesterase in aging rhesus monkeys.
Gabelt BT; Kaufman PL; Polansky JR
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2431-6. PubMed ID: 2243006
[TBL] [Abstract][Full Text] [Related]
8. Differential alterations of cholinergic muscarinic receptors during chronic and acute tolerance to organophosphorus insecticides.
Costa LG; Schwab BW; Murphy SD
Biochem Pharmacol; 1982 Nov; 31(21):3407-13. PubMed ID: 7150362
[TBL] [Abstract][Full Text] [Related]
9. [Circadian changes of acetylcholine, choline acetyltransferase, acetylcholinesterase and muscarinic receptors in mouse brain].
Pan SY
Zhongguo Yao Li Xue Bao; 1991 Mar; 12(2):148-51. PubMed ID: 1776479
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological study of oral CDP-choline. Interaction with oxotremorine on the parasympathetic system.
Tornos ME; Sacristán A; Ortiz JA
Arzneimittelforschung; 1983; 33(7A):1026-9. PubMed ID: 6684457
[TBL] [Abstract][Full Text] [Related]
11. Oxotremorine-tolerance: muscarinic blockade or homeostatic adaptation?
György L
Acta Physiol Acad Sci Hung; 1979; 53(1):55-9. PubMed ID: 495126
[TBL] [Abstract][Full Text] [Related]
12. Cross-tolerance between muscarinic agonists: role of muscarinic receptors.
Collins AC; Smolen TN; Smolen A; Medhurst LJ
Pharmacol Biochem Behav; 1987 Jan; 26(1):173-82. PubMed ID: 3562489
[TBL] [Abstract][Full Text] [Related]
13. Regulation of brain acetylcholine concentration by muscarinic receptors.
Sethy VH; Francis JW
J Pharmacol Exp Ther; 1988 Jul; 246(1):243-8. PubMed ID: 3392656
[TBL] [Abstract][Full Text] [Related]
14. The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats.
Srikumar BN; Raju TR; Shankaranarayana Rao BS
Neuroscience; 2006 Dec; 143(3):679-88. PubMed ID: 17008021
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic system in experimental rabies in mice.
Jackson AC
Acta Virol; 1993 Dec; 37(6):502-8. PubMed ID: 8010187
[TBL] [Abstract][Full Text] [Related]
16. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
17. Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine.
Marks MJ; Collins AC
Pharmacol Biochem Behav; 1985 Feb; 22(2):283-91. PubMed ID: 3983219
[TBL] [Abstract][Full Text] [Related]
18. On the interaction of drugs with the cholinergic nervous system--IV. Tolerance to oxotremorine in mice: in vivo and in vitro studies.
Maayani S; Egozi Y; Pinchasi I; Sokolovsky M
Biochem Pharmacol; 1977 Sep; 26(18):1681-7. PubMed ID: 901587
[No Abstract] [Full Text] [Related]
19. Muscarinic receptor alterations as a mechanism of anticholinesterase tolerance.
Schwab BW; Costa LG; Murphy SD
Toxicol Appl Pharmacol; 1983 Oct; 71(1):14-23. PubMed ID: 6636179
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain.
Garofalo L; Cuello AC
J Pharmacol Exp Ther; 1995 Feb; 272(2):527-45. PubMed ID: 7853166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
